Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283285 | 0.95 | ESR2 (0.70) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| SCHEMBL12485928 | 0.92 | ESR1 (0.55) | ESR1ESR2HDAC6HDAC8PKM | |
| SCHEMBL10214641 | 0.89 | HDAC6 (0.56) | ESR1ESR2HDAC6HDAC8ABHD6 | |
| SCHEMBL31670429 | 0.86 | ESR1 (0.68) | ESR1ESR2HDAC6HDAC8PKM | |
| SCHEMBL4704441 | 0.86 | ESR1 (0.68) | ESR1ESR2HDAC6HDAC8PKM | |
| SCHEMBL14101079 | 0.85 | ESR1 (0.70) | ESR1ESR2HDAC6HDAC8PKM | |
| SCHEMBL30810841 | 0.85 | HDAC6 (0.51) | ESR1ESR2HDAC6HDAC8MAPK1 | |
| SCHEMBL17560214 | 0.85 | NOTUM (0.56) | ESR1ESR2HDAC6HDAC8MAPK1 | |
| SCHEMBL2277266 | 0.85 | HDAC6 (0.51) | ESR1ESR2HDAC6HDAC8MAPK1 | |
| SCHEMBL14101201 | 0.84 | ESR1 (0.58) | ESR1ESR2HDAC6HDAC8PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602811-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2017133521-A1 | FXR RECEPTOR AGONIST | 山东轩竹医药科技有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2012117421-A1 | HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD (IN) | 2012-09-07 | — | — | WO | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PDE5A, PDE3A, PDE3B | ESR1 4778/4885ESR2 4646/4885HDAC6 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.